Stockscreener 앱 받기
4.63
2.32%
-0.11
시간 외 거래:
4.63
Cns Pharmaceuticals Inc 주식(CNSP)의 최신 뉴스
Why did CNSP stock surge 330% today? - MSN
CNSP Q1 2026 Earnings: Wider Than Expected Loss, No Revenue Reported; Stock Rises 3.6%Estimate Revision Count - newsline.com
CNS Pharmaceuticals (CNSP) Tests Key Levels After Modest GainBreadth Thrust - newsline.com
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation - TradingView
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Cash Burn and Pipeline ChallengesPretax Income Report - newsline.com
CNS Pharmaceuticals Highlights Oversubscribed $22.5 Million Financing and Growth Strategy - citybuzz -
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - ACCESS Newswire
Biotech CFO breaks down oversubscribed $22.5M raise and strategy shift - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
CNS Pharmaceuticals (CNSP) Shows Resilience with 2% Gain, Testing Key ResistanceSeasonality Effect - newsline.com
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - newsline.com
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Advances - newsline.com
CNS Pharmaceuticals Surges 11% as Biotech Sector Shows Renewed InterestDeath Cross - The Legal Advocate
CNS Pharmaceuticals (CNSP) Faces Selling Pressure as Shares Decline Over 5%Total Put Call - The Legal Advocate
CNS (CNSP) Suffers -4.49% Decline on Heavy Selling 2026-05-28Initial Balance - newsline.com
Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight - GlobeNewswire Inc.
[EFFECT] CNS Pharmaceuticals, Inc. SEC Filing - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) registers 9.79M resale shares from May private placement - Stock Titan
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress - Bluefield Daily Telegraph
Insider Buying: Faith Charles Acquires Shares of CNS Pharmaceuti - GuruFocus
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock By Investing.com - Investing.com Canada
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock - Investing.com
CNSP | CNS Pharmaceuticals, Inc. Common Insider Trading - Quiver Quantitative
CNS Pharmaceuticals raises $22.5M to advance new biotech therapies and strategic growth. - Pluang
[Form 4] CNS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders - Moomoo
CNS Pharmaceuticals (CNSP) registers 9.79M shares including prefunded warrants - Stock Titan
cns pharmaceuticals inc Earnings dates - RTTNews
NRXP: Advanced CNS drug pipeline, reduced net loss, and expanded clinical footprint in Q1 2026 - TradingView
CNS Pharmaceuticals, Inc. announced that it has received $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners and other investors - marketscreener.com
Stonepine (CNSP) reports 159,790 shares; 9.9% position disclosed - Stock Titan
Maxim Group Maintains CNS Pharmaceuticals(CNSP.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Addex Therapeutics (ADXN.SW) Jumps 6.7% as CNS Drug Pipeline Advances - Meyka
CNSP Poised for Growth Through Strategic Initiatives - GuruFocus
CNS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CNSP's Financial Outlook After Recent Fundraising - GuruFocus
CNS Pharmaceuticals, Inc. Q1 2026 Financials and Corporate Strategy Update – 10-Q Report Highlights - Minichart
CNS Pharmaceuticals : CNSP - 24/7 Wall St.
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transforma - PharmiWeb.com
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress - ACCESS Newswire
Biotech CNS Pharmaceuticals secures $22.5M to buy neurology, oncology drugs - Stock Titan
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CNS Pharmaceuticals (CNSP) widens Q1 loss but secures $22.5M private placement - Stock Titan
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6 - 24/7 Wall St.
TradingKey - TradingKey
CNS Pharmaceuticals Inc expected to post a loss of $5.37 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
1.27%
1.43%
자본화:
|
볼륨(24시간):